|
Velpatasvir-Based Regimens in Treatment-Naïve and Treatment-Experienced Adults with Resistant HCV GT4 Subtypes Endemic to Sub-Saharan Africa
Findings from the SHARED-3 Study in Rwanda
 
|
|
|
Presenting Author: Dr. Fabienne Shumbusho
Other Authors: Fredrick Kateera, Linda Manirambona, Jules Kabihizi, Anthere Murangwa, Janvier Serumondo, Jean Damascene Makuza, Sabin Nsanzimana, Claude Muvunyi, Emmanuel Musabeyezu, Greg Camus, Philip M Grant, Neil Gupta  
AASLD: RARE HCV GENOTYPES: PREVALENCE AND RESISTANCE-ASSOCIATED SUBSTITUTIONS IN DAA-NAÏVE AND DAA-EXPERIENCED PATIENTS (12/01/21)  
AASLD: LONG-TERM PERSISTENCE OF RESISTANCE-ASSOCIATED SUBSTITUTIONS (RASS) AFTER DAA TREATMENT FAILURE IN PATIENTS WITH CHRONIC HCV INFECTION (12/01/21)  
AASLD: Treat HCV Early; SOF/DCV Had Lower SVR Rates (11/30/21)
![1206211](../images/120621/120621-7/1206211.gif)
![1206212](../images/120621/120621-7/1206212.gif)
![1206213](../images/120621/120621-7/1206213.gif)
![1206214](../images/120621/120621-7/1206214.gif)
![1206215](../images/120621/120621-7/1206215.gif)
![1206216](../images/120621/120621-7/1206216.gif)
| |
|
|
|
|
|